AU5187190A - Improved baculovirus expression system capable of producing foreign gene proteins at high levels - Google Patents

Improved baculovirus expression system capable of producing foreign gene proteins at high levels

Info

Publication number
AU5187190A
AU5187190A AU51871/90A AU5187190A AU5187190A AU 5187190 A AU5187190 A AU 5187190A AU 51871/90 A AU51871/90 A AU 51871/90A AU 5187190 A AU5187190 A AU 5187190A AU 5187190 A AU5187190 A AU 5187190A
Authority
AU
Australia
Prior art keywords
high levels
system capable
expression system
foreign gene
baculovirus expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51871/90A
Inventor
C. Yong Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Ottawa
Original Assignee
University of Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA000591908A external-priority patent/CA1330425C/en
Priority claimed from US07/316,768 external-priority patent/US5194376A/en
Application filed by University of Ottawa filed Critical University of Ottawa
Publication of AU5187190A publication Critical patent/AU5187190A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU51871/90A 1989-02-23 1990-02-23 Improved baculovirus expression system capable of producing foreign gene proteins at high levels Abandoned AU5187190A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA591908 1989-02-23
CA000591908A CA1330425C (en) 1989-02-23 1989-02-23 Baculovirus expression system capable of producing foreign gene proteins at high levels
US316768 1989-02-28
US07/316,768 US5194376A (en) 1989-02-28 1989-02-28 Baculovirus expression system capable of producing foreign gene proteins at high levels

Publications (1)

Publication Number Publication Date
AU5187190A true AU5187190A (en) 1990-09-26

Family

ID=25672469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51871/90A Abandoned AU5187190A (en) 1989-02-23 1990-02-23 Improved baculovirus expression system capable of producing foreign gene proteins at high levels

Country Status (2)

Country Link
AU (1) AU5187190A (en)
WO (1) WO1990010078A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631223B2 (en) * 1989-05-17 1992-11-19 University Of Georgia Research Foundation, Inc., The Improved baculovirus expression vectors

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
AU2005265163B2 (en) 2004-06-18 2009-10-01 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
SG158149A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN103290084A (en) 2004-12-22 2013-09-11 Ambrx公司 Method for expression and purification of recombinant human growth hormone
EP1893229B1 (en) 2005-06-03 2011-10-19 Ambrx, Inc. Improved human interferon molecules and their uses
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
CA2662753C (en) 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
JP5451390B2 (en) 2006-09-08 2014-03-26 アンブルックス，インコーポレイテッド Transcription of suppressor TRNA in vertebrate cells
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX338336B (en) 2007-11-20 2016-04-07 Ambrx Inc Modified insulin polypeptides and their uses.
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
ES2963062T3 (en) 2008-07-23 2024-03-25 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
EA019653B1 (en) 2008-09-26 2014-05-30 Амбркс Инк. Modified animal erythropoietin polypeptides and their uses
TR201802361T4 (en) 2008-09-26 2018-03-21 Ambrx Inc Microorganisms and vaccines dependent on unnatural amino acid replication.
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
MX346786B (en) 2010-08-17 2017-03-31 Ambrx Inc Modified relaxin polypeptides and their uses.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
EP3909596A1 (en) 2014-10-24 2021-11-17 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
MY193457A (en) 2017-02-08 2022-10-14 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631223B2 (en) * 1989-05-17 1992-11-19 University Of Georgia Research Foundation, Inc., The Improved baculovirus expression vectors

Also Published As

Publication number Publication date
WO1990010078A1 (en) 1990-09-07

Similar Documents

Publication Publication Date Title
AU5187190A (en) Improved baculovirus expression system capable of producing foreign gene proteins at high levels
AU7469787A (en) Process for the genetic modification of yeast
AU3952389A (en) Comfortable fabrics of high durability
AU6844290A (en) Implant having varying modulus of elasticity
AU6053090A (en) Manufacture of carbon fibre preform
IL96765A0 (en) Modification of the expression characteristics of an endogenous gene
AU574944B2 (en) Refining of glass
AU7984287A (en) Proteins of aids envelope gene
AU1482488A (en) Leader sequences for the production of recombinant proteins
AU7831787A (en) Improved recombinant expression
AU6067190A (en) Improved stable coagulation controls
AU636884B2 (en) Optimisation of cleaning
AU7787191A (en) Improved bioreactor surfaces and methods of making same
AU1406497A (en) Mutational variants of mammalian ob gene proteins
AU627565B2 (en) Process for the preparation of cefodizime sodium
AU7312787A (en) Improved tandem-axle walking beam suspension
AU623837B2 (en) Process for decantation of suspensions
AU5567090A (en) Purification of proteins employing ctap-iii fusions
AU2710388A (en) Acceleration of bone formation with gm-csf
AU625234B2 (en) Stabilization of glycosylized t-pa
AU5160690A (en) Detection of pyrogens by recombinant mammalian cells
AU6603090A (en) Enzymatic production of d-amino acids
AU5006990A (en) Milled proteins
GB8904426D0 (en) Improved baculovirus expression system capable of producing foreign gene proteins at high levels
AU6357890A (en) Expression of alpha-macroglobulins